RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GlaxoSmithKline Stock

GlaxoSmithKline EBIT 2024

GlaxoSmithKline EBIT

8.8 B GBP

Ticker

GSK.L

ISIN

GB0009252882

WKN

940561

In 2024, GlaxoSmithKline's EBIT was 8.8 B GBP, a 6.02% increase from the 8.3 B GBP EBIT recorded in the previous year.

The GlaxoSmithKline EBIT history

YEAREBIT (undefined GBP)
2029e-
2028e12.46
2027e12.35
2026e10.93
2025e9.83
2024e8.8
20238.3
20228.4
20215.75
20205.99
20198.88
20188.36
20177.99
20167.04
20154.97
20145.48
20137.2
20127.88
20118.18
20104.96
20098.82
20088.04
20077.36
20067.62
20056.6
20046.09

GlaxoSmithKline Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GlaxoSmithKline, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GlaxoSmithKline from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GlaxoSmithKline’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GlaxoSmithKline. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GlaxoSmithKline’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GlaxoSmithKline’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GlaxoSmithKline’s growth potential.

GlaxoSmithKline Revenue, EBIT and net profit per share

DateGlaxoSmithKline RevenueGlaxoSmithKline EBITGlaxoSmithKline Net Income
2029e39.33 B undefined0 undefined8.72 B undefined
2028e39.05 B undefined12.46 B undefined9.25 B undefined
2027e38.64 B undefined12.35 B undefined9.08 B undefined
2026e36.47 B undefined10.93 B undefined8.2 B undefined
2025e34.42 B undefined9.83 B undefined7.38 B undefined
2024e32.57 B undefined8.8 B undefined6.71 B undefined
202330.33 B undefined8.3 B undefined4.93 B undefined
202229.32 B undefined8.4 B undefined14.96 B undefined
202124.7 B undefined5.75 B undefined4.39 B undefined
202024.35 B undefined5.99 B undefined5.75 B undefined
201933.75 B undefined8.88 B undefined4.65 B undefined
201830.82 B undefined8.36 B undefined3.62 B undefined
201730.19 B undefined7.99 B undefined1.53 B undefined
201627.89 B undefined7.04 B undefined912 M undefined
201523.92 B undefined4.97 B undefined8.42 B undefined
201423.01 B undefined5.48 B undefined2.76 B undefined
201326.51 B undefined7.2 B undefined5.44 B undefined
201226.43 B undefined7.88 B undefined4.57 B undefined
201127.39 B undefined8.18 B undefined5.26 B undefined
201028.39 B undefined4.96 B undefined1.63 B undefined
200928.37 B undefined8.82 B undefined5.53 B undefined
200824.35 B undefined8.04 B undefined4.6 B undefined
200722.72 B undefined7.36 B undefined5.21 B undefined
200623.23 B undefined7.62 B undefined5.39 B undefined
200521.66 B undefined6.6 B undefined4.69 B undefined
200420.36 B undefined6.09 B undefined4.3 B undefined

GlaxoSmithKline stock margins

The GlaxoSmithKline margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GlaxoSmithKline. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GlaxoSmithKline.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GlaxoSmithKline's sales revenue. A higher gross margin percentage indicates that the GlaxoSmithKline retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GlaxoSmithKline's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GlaxoSmithKline's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GlaxoSmithKline's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GlaxoSmithKline. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GlaxoSmithKline's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GlaxoSmithKline Margin History

GlaxoSmithKline Gross marginGlaxoSmithKline Profit marginGlaxoSmithKline EBIT marginGlaxoSmithKline Profit margin
2029e72.42 %0 %22.18 %
2028e72.42 %31.9 %23.7 %
2027e72.42 %31.96 %23.51 %
2026e72.42 %29.97 %22.48 %
2025e72.42 %28.56 %21.46 %
2024e72.42 %27.03 %20.6 %
202372.42 %27.38 %16.25 %
202271.13 %28.63 %51 %
202167.58 %23.28 %17.76 %
202069.94 %24.61 %23.61 %
201969.88 %26.32 %13.76 %
201868.94 %27.13 %11.75 %
201769.13 %26.46 %5.08 %
201668.09 %25.26 %3.27 %
201566.38 %20.76 %35.2 %
201469.41 %23.82 %11.98 %
201369.82 %27.16 %20.51 %
201271.79 %29.82 %17.27 %
201173.49 %29.85 %19.21 %
201073.92 %17.46 %5.76 %
200974.99 %31.08 %19.5 %
200876.28 %33.01 %18.9 %
200776.59 %32.39 %22.95 %
200678.43 %32.83 %23.2 %
200578.01 %30.47 %21.65 %
200478.83 %29.91 %21.13 %

GlaxoSmithKline Aktienanalyse

What does GlaxoSmithKline do?

GlaxoSmithKline PLC is a globally leading pharmaceutical company headquartered in London, UK. The company's history dates back to 1873 when the Burroughs Wellcome & Co firm was founded. In 2000, the company merged with Glaxo Wellcome to form the current GlaxoSmithKline PLC. GlaxoSmithKline's business model is to provide medical solutions for various diseases and health problems. The company heavily invests in research and development to develop new drugs and vaccines. It collaborates closely with government agencies, hospitals, doctors, and patient organizations to ensure better access to its products. The company is divided into three different divisions: Pharma, Vaccines, and Consumer Healthcare. The Pharma division is the largest and includes areas such as oncology, immunology, neuroscience, respiratory, and infectious diseases. GlaxoSmithKline is a leader in HIV treatment and is also active in the development of cancer drugs. The Vaccines division of GlaxoSmithKline is also very large and includes vaccines against various infectious diseases such as pneumococcus, influenza, and meningitis. It is also working on the development of vaccines against COVID-19. GlaxoSmithKline's Consumer Healthcare division includes products such as Sensodyne, Voltaren, Nicotinell, and Aquafresh. These products operate in the areas of oral health, pain relief, and smoking cessation. The focus is on a wide range of over-the-counter products available in pharmacies and supermarkets. An example of an important product of GlaxoSmithKline is the malaria vaccine developed in collaboration with the University of Oxford. The vaccine has the potential to save millions of lives in Africa. Currently, the vaccine is being tested in several African countries. GlaxoSmithKline PLC has also faced some controversies in the past, particularly related to the marketing of antidepressants. However, the company has taken measures to increase the transparency of its practices and operate ethically. Overall, GlaxoSmithKline is a significant pharmaceutical company that offers a wide range of medical products and solutions. It heavily invests in research and development to develop new products that can improve people's lives. The company also adopts an ethical approach in its business and advocates for better access to its products. GlaxoSmithKline ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing GlaxoSmithKline's EBIT

GlaxoSmithKline's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of GlaxoSmithKline's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

GlaxoSmithKline's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in GlaxoSmithKline’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about GlaxoSmithKline stock

How much did GlaxoSmithKline achieve in EBIT for the current year?

In the current year, GlaxoSmithKline has achieved an EBIT of 8.8 B GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company GlaxoSmithKline.

How has the EBIT of GlaxoSmithKline developed in recent years?

The EBIT of GlaxoSmithKline has increased by 6.021% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company GlaxoSmithKline?

The EBIT of GlaxoSmithKline is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does GlaxoSmithKline pay?

Over the past 12 months, GlaxoSmithKline paid a dividend of 0.56 GBP . This corresponds to a dividend yield of about 3.77 %. For the coming 12 months, GlaxoSmithKline is expected to pay a dividend of 1.04 GBP.

What is the dividend yield of GlaxoSmithKline?

The current dividend yield of GlaxoSmithKline is 3.77 %.

When does GlaxoSmithKline pay dividends?

GlaxoSmithKline pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of GlaxoSmithKline?

GlaxoSmithKline paid dividends every year for the past 26 years.

What is the dividend of GlaxoSmithKline?

For the upcoming 12 months, dividends amounting to 1.04 GBP are expected. This corresponds to a dividend yield of 7.04 %.

In which sector is GlaxoSmithKline located?

GlaxoSmithKline is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlaxoSmithKline kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlaxoSmithKline from 10/10/2024 amounting to 0.15 GBP, you needed to have the stock in your portfolio before the ex-date on 8/15/2024.

When did GlaxoSmithKline pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of GlaxoSmithKline in the year 2023?

In the year 2023, GlaxoSmithKline distributed 0.67 GBP as dividends.

In which currency does GlaxoSmithKline pay out the dividend?

The dividends of GlaxoSmithKline are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The GlaxoSmithKline stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von GlaxoSmithKline

Our stock analysis for GlaxoSmithKline Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlaxoSmithKline Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.